biotech thread - wednesday 31st october , page-2

Add in the winners and losers BTA. Perhaps you should add another title - "Sad". Just a huge amount of small holders and funds who didn't wish to hold offshore shares so huge price pressure on something that possibly should have been held in super for value to eventuate under a better management in the future. BTA could be a case study for Australian biotech and how it can go right and then down the drain. Lot of lessons that will repeat in other companies